An intravenous infusion of oxytocin is used to induce labor and to support labor in case of slow childbirth.Oxytocin is also used in veterinary medicine to facilitate birth and to stimulate milk release.
Registration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
Synonyms/Alias | OXYTOCIN;50-56-6;Pitocin;Endopituitrina;Ocytocin;Syntocinon;Oxytocinum;Orasthin;Oxitocina;Oxystin;Oxytocine;alpha-Hypophamine;Partocon;Synthetic oxytocin;Piton S;(1-Hemicystine)oxytocin;3-Isoleucine-8-leucine vasopressin;Syntocinone;Ocytocinum;Ossitocina;Oxetakain;Oxoject;Presoxin;Synpitan;Syntocin;Utedrin;Uteracon;Di-sipidin;Nobitocin S;Atonin O;Intertocine S;UNII-1JQS135EYN;HSDB 2182;Oxytocine [INN-French];Oxytocinum [INN-Latin];EINECS 200-048-4;Oxitocina [INN-Spanish];MFCD00076731;BRN 3586108;Vasopressin, 3-L-isoleucine-8-L-leucine-;CHEBI:7872;CHEMBL395429;(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide;OT;DTXSID8048361;OXYTOCIN 5 USP UNITS IN DEXTROSE 5%;Oxytocin [USP:INN:BAN:JAN];OXYTOCIN 10 USP UNITS IN DEXTROSE 5%;OXYTOCIN 20 USP UNITS IN DEXTROSE 5%;TNX1900;TTA-121;TNX-1900;OXT;Oxytocine (INN-French);Oxytocinum (INN-Latin);Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, cyclic 1-6 disulfide;Oxitocina (INN-Spanish);L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic (1-->6)-disulfide;L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic (1-6)-disulfide;L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide;Oxytocin (USP:INN:BAN:JAN);[3H]oxytocin;Oxetakain [Czech];1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide;Otx;Ossitocina [DCIT];C43H66N12O12S2;[3H]OT (human, mouse, rat);Piton-S;Syntocinon (TN);Oxytocin Injectable;Oxytocin (TN);Oxytocin,(S);(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide;1-(((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-((1S)-1-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl)carbonyl)-L-prolyl-L-leucylglycinamide;Pitocin (TN);CYIQNCPLG;oxytocin, for bioassay;PVL Oxytocin Injectable;(1-Hemicystine)-oxytocin;OXYTOCIN (MART.);OXYTOCIN (USP-RS);1JQS135EYN;SCHEMBL29048;Oxytocin (JP18/USP/INN);GTPL2174;GTPL2176;Oxytocin (High Potency Powder);OXYTOCIN (USP IMPURITY);DTXCID4028335;OXYTOCIN (USP MONOGRAPH);BCBcMAP01_000094;H01BB02;Oxytocin (Label Under Distributors);BDBM50205990;HB2929;TI-001;AKOS015994657;FO35402;HS-2021;NCGC00167132-01;AC-28730;HY-17571;C00746;D00089;SBI-0654087.0001;Q169960;SR-01000945111;SR-01000945111-1;BRD-K25243230-001-01-2;Oxytocin, European Pharmacopoeia (EP) Reference Standard;(Gly-9 = C-terminal amide, disulfide bridge between 1 - 6);Oxytocin, United States Pharmacopeia (USP) Reference Standard;Oxytocin-(leucine-5,5,5-d3, glycine-2,2-d2) trifluoroacetate salt;Oxytocin, lyophilized powder, ~15 IU/mg solid (Prepared from synthetic oxytocin);200-048-4;GLYCINAMIDE, L-CYSTEINYL-L-TYROSYL-L-ISOLEUCYL-L-GLUTAMINYL-L-ASPARAGINYL-L-CYSTEINYL-L-PROLYL-L-LEUCYL-, CYCLIC (1->6)-DISULFIDE;Glycinamide, L-cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-propyl-L-leucyl-, cyclic (1-6)-di-; |
M.F/Formula | C43H66N12O12S2 |
M.W/Mr. | 1007.2 |
Sequence | One Letter Code:CYIQNCPLG Three Letter Code:H-Cys(1)-Tyr-Ile-Gln-Asn-Cys(1)-Pro-Leu-Gly-NH2 |
Appearance | White Solid |
Biological Activity | Neurohypophyseal peptide. Stimulates uterine contraction and lactation. |
Length | 9 |
Long-term Storage Conditions | Soluble to 1 mg/ml in water |
Shipping Condition | Room temperature in continental US; may vary elsewhere. |
InChI | InChI=1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1 |
InChI Key | XNOPRXBHLZRZKH-DSZYJQQASA-N |
3. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs
4. Cationic cell-penetrating peptides are potent furin inhibitors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com